Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials

SUMMARY: In a combined analysis of 25,389 postmenopausal women aged 50–79 years, enrolled in the two Women’s Health Initiative hormone therapy trials, menopausal hormone therapy vs. placebo reduced the risk of fracture regardless of baseline FRAX fracture probability and falls history. INTRODUCTION:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorentzon, Mattias, Johansson, Helena, Harvey, Nicholas C., Liu, Enwu, Vandenput, Liesbeth, Crandall, Carolyn J., Cauley, Jane A., LeBoff, Meryl S., McCloskey, Eugene V., Kanis, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568435/
https://www.ncbi.nlm.nih.gov/pubmed/35833956
http://dx.doi.org/10.1007/s00198-022-06483-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568435/
https://www.ncbi.nlm.nih.gov/pubmed/35833956
http://dx.doi.org/10.1007/s00198-022-06483-y

Ejemplares similares